MARIO ALAMILLA-SANCHEZ

Dr. MARIO ALAMILLA-SANCHEZ

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 July 2025 in Pathophysiology
Verified
Journal Article
Open access
PDF file
MARIO ALAMILLA-SANCHEZMARIO ALAMILLA-SANCHEZ
MARIO ALAMILLA-SANCHEZ
MSMiguel Angel Alcalá Salgado
Miguel Angel Alcalá Salgado
VGVictor Manuel Ulloa Galvan
Victor Manuel Ulloa Galvan
VSValeria Yanez Salguero
Valeria Yanez Salguero
MEMartín Benjamin Yamá Estrella
Martín Benjamin Yamá Estrella
JGJulio Manuel Flores Garnica
Julio Manuel Flores Garnica
Renal function refers to the combined actions of the glomerulus and tubular system to achieve homeostasis in bodily fluids. While the glomerulus is essential in the first step of urine formation through a coordinated filtration mechanism, the tubular system carries out active mechanisms of secretion and reabsorption of solutes and proteins using specific transporters in the epithelial cells. The assessment of renal function usually focuses on glomerular function, so the tubular function is often underestimated as a fundamental part of daily clinical practice. Therefore, it is essential to properly understand the tubular physiological mechanisms and their clinical association with prevalent human pathologies. This review discusses the primary solutes handled by the kidneys, including glucose, amino acids, sodium, potassium, calcium, phosphate, citrate, magnesium and uric acid. Additionally, it emphasizes the significance of physicochemical characteristics of urine, such as pH and osmolarity. The use of a concise methodology for the comprehensive assessment of urine should be strengthened in the basic training of nephrologists when dealing with problems such as water and electrolyte balance disorders, acid-base disorders, and harmful effects of commonly used drugs such as chemotherapy, antibiotics, or diuretics to avoid isolated replacement of the solute without carrying out comprehensive approaches, which can lead to potentially severe complications.

4 January 2023 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GFG. Fonseca-González
G. Fonseca-González
MARIO ALAMILLA-SANCHEZMARIO ALAMILLA-SANCHEZ
MARIO ALAMILLA-SANCHEZ
VGV. García-Macas
V. García-Macas
JHJ. Herrera-Acevedo
J. Herrera-Acevedo
MVM. Villalobos-Brito
M. Villalobos-Brito
JSJuan Antonio Suárez-Cuenca
Juan Antonio Suárez-Cuenca
The clinical course of COVID-19 may show severe presentation, potentially involving dynamic cytokine storms and T cell lymphopenia, which are leading causes of death in patients with SARS-CoV-2 infection. Plasma exchange therapy (PLEX) effectively removes pro-inflammatory factors, modulating and restoring innate and adaptive immune responses. This clinical trial aimed to evaluate the impact of PLEX on the survival of patients with severe SARS-CoV-2 and the effect on the cytokine release syndrome. Hospitalized patients diagnosed with SARS-CoV-2 infection and cytokine storm syndrome were selected to receive 2 sessions of PLEX or standard therapy. Primary outcome was all-cause 60-days mortality; secondary outcome was requirement of mechanical ventilation, SOFA, NEWs-2 scores modification, reduction of pro-inflammatory biomarkers and hospitalization time. Twenty patients received PLEX were compared against 40 patients receiving standard therapy. PLEX reduced 60-days mortality (50% vs 20%; OR 0.25, 95%CI 0.071–0.880; p = 0.029), and this effect was independent from demographic variables and drug therapies used. PLEX significantly decreased SOFA, NEWs-2, pro-inflammatory mediators and increased lymphocyte count, accompanied with a trend to reduce affected lung volume, without effect on SatO2/FiO2 indicator or mechanical ventilation requirement. PLEX therapy provided significant benefits of pro-inflammatory clearance and reduction of 60-days mortality in selected patients with COVID-19, without significant adverse events.

1 December 2021 in International Journal of Nephrology and Renovascular Disease
Verified
Journal Article
Open access
PDF file
MARIO ALAMILLA-SANCHEZMARIO ALAMILLA-SANCHEZ
MARIO ALAMILLA-SANCHEZ
MAMiguel A Alcala-Salgado
Miguel A Alcala-Salgado
CACesar D Alonso-Bello
Cesar D Alonso-Bello
GFGandhy T Fonseca-Gonzalez
Gandhy T Fonseca-Gonzalez
Approximately 70% of the patients with systemic lupus erythematosus will have clinical evidence of kidney damage during their evolution. Patients with impaired renal function at onset and those with recurrent flares have a poor prognosis. Understanding the mechanism of action of immunosuppressants is essential for proper prescription. Steroids inhibit the DNA sequence that promotes the release of inflammatory cytokines. Phosphoramide mustard, metabolite of cyclophosphamide, cross-link with the DNA, causing the aggregation of an alkyl group, causing cell death. Mycophenolate inhibits inosine monophosphate dehydrogenase, prevents de novo synthesis of guanine, inducing cell arrest in S phase. Azathioprine blocks the synthesis of purines and induces apoptosis. Calcineurin inhibitors prevent the dephosphorylation of NFAT and reduce the production of interleukin 2. Antimalarials alter the enzymatic release of lysosomes by increasing intravesicular pH. The mechanism of action of rituximab is related to complement-dependent cytotoxicity and the elimination of anti-CD20-labeled B cells. Progress in the knowledge and management of low doses of steroids may change the current paradigm and reduce the frequency of related adverse events. Mycophenolate seems to be a better choice than cyclophosphamide for induction, it is also preferred over azathioprine as a maintenance immunosuppressive agent, although azathioprine is preferred in women with a desire for conception, those pregnant, or with low resources. For treatment-resistant cases, tacrolimus, rituximab or belimumab may be effective. Ongoing clinical trials with new drugs offer promising results.

30 June 2023 in International Journal of General Medicine
Verified
Journal Article
Open access
PDF file
MARIO ALAMILLA-SANCHEZMARIO ALAMILLA-SANCHEZ
MARIO ALAMILLA-SANCHEZ
MAMiguel A Alcala-Salgado
Miguel A Alcala-Salgado
BSBeatriz Cerezo Samperio
Beatriz Cerezo Samperio
PLPamela Prado Lozano
Pamela Prado Lozano
JGJUAN DANIEL DIAZ GARCIA
JUAN DANIEL DIAZ GARCIA
ELEnrique Fleuvier Morales Lopez
Enrique Fleuvier Morales Lopez
The Starling principle is a model that explains the transvascular distribution of fluids essentially governed by hydrostatic and oncotic forces, which dynamically allow vascular refilling according to the characteristics of the blood vessel. However, careful analysis of fluid physiology has shown that the principle, while correct, is not complete. The revised Starling principle (Michel-Weinbaum model) provides relevant information on fluid kinetics. Special emphasis has been placed on the endothelial glycocalyx, whose subendothelial area allows a restricted oncotic pressure that limits the reabsorption of fluid from the interstitial space, so that transvascular refilling occurs mainly from the lymphatic vessels. The close correlation between pathological states of the endothelium (eg: sepsis, acute inflammation, or chronic kidney disease) and the prescription of fluids forces the physician to understand the dynamics of fluids in the organism; this will allow rational fluid prescriptions. A theory that integrates the physiology of exchange and transvascular refilling is the “microconstant model”, whose variables include dynamic mechanisms that can explain edematous states, management of acute resuscitation, and type of fluids for common clinical conditions. The clinical-physiological integration of the concepts will be the hinges that allow a rational and dynamic prescription of fluids.

1 January 2014 in NCT Neumología y Cirugía de Tórax
Verified
Journal Article
Closed access
PDF file
ARAna Lilia Nolasco-De la Rosa
Ana Lilia Nolasco-De la Rosa
CHCarlos Enrique Hermida-Escobedo
Carlos Enrique Hermida-Escobedo
MARIO ALAMILLA-SANCHEZMARIO ALAMILLA-SANCHEZ
MARIO ALAMILLA-SANCHEZ
CPCésar Pedraza-Hervert
César Pedraza-Hervert

1 January 2021 in Revista Mexicana de Trasplantes
Verified
Journal Article
Closed access
PDF file
GTGandhy Thomas-Fonseca
Gandhy Thomas-Fonseca
HCHoracio Cano-Cervantes
Horacio Cano-Cervantes
SHSergio Hernández-Estrada
Sergio Hernández-Estrada
ODOdette Díaz-Avendaño
Odette Díaz-Avendaño
MARIO ALAMILLA-SANCHEZMARIO ALAMILLA-SANCHEZ
MARIO ALAMILLA-SANCHEZ
VGVanessa García-Macas
Vanessa García-Macas